VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Virax Biolabs Group Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026
$1.40−0.05 (-3.45%)
Close on Oct 19, 2026
Market cap
–
P/E (TTM)
–
Dividend yield
–
Virax Biolabs statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of In Vitro & In Vivo Diagnostic Substances companies for comparison
Valuation
Measure
Virax Biolabs
Industry median
Market Cap
$810.91K
$166.30M
Enterprise Value
-$5.87M
$88.19M
PS Ratio
65.27
3.65
PB Ratio
0.11
2.03
P/TBV Ratio
0.11
2.29
Enterprise value
Measure
Virax Biolabs
Industry median
EV / Sales
-472.54
2.51
Income (trailing twelve months)
Measure
Virax Biolabs
Industry median
Revenue
$12.42K
$58.34M
Gross Profit
$7.69K
$105.94M
Operating Income
-$6.40M
-$21.40M
Pretax Income
-$5.93M
-$14.34M
Net Income
-$5.02M
-$22.46M
EBITDA
-$6.40M
-$16.91M
EPS (Diluted)
-$12.64
-$0.83
Margins
Measure
Virax Biolabs
Industry median
Gross Margin
61.9%
52.9%
Operating Margin
-51515.2%
-44.0%
Pretax Margin
-47753.6%
-13.3%
Profit Margin
-40439.1%
-40.2%
EBITDA Margin
-51515.2%
-30.2%
FCF Margin
-39263.6%
-9.27%
Returns
Measure
Virax Biolabs
Industry median
Return on Equity (ROE)
-75.7%
-53.2%
Return on Assets (ROA)
-68.1%
-40.9%
Return on Invested Capital (ROIC)
-388.1%
-32.4%
Return on Capital Employed (ROCE)
-83.8%
-38.1%
Growth
Measure
Virax Biolabs
Industry median
Revenue Growth (YoY)
96.2%
5.96%
Revenue Growth (3Y CAGR)
13.2%
2.25%
Revenue Growth (5Y CAGR)
-36.9%
6.48%
Balance sheet
Measure
Virax Biolabs
Industry median
Cash & Short-Term Investments
$6.44M
$61.43M
Net Cash (Debt)
$6.44M
$15.35M
Net Cash Per Share
$11.12
$0.66
Equity (Book Value)
$7.58M
$49.09M
Book Value Per Share
$13.08
$1.37
Tangible Book Value
$7.58M
$23.52M
Working Capital
$6.14M
$76.81M
Financial position
Measure
Virax Biolabs
Industry median
Current Ratio
9.97
3.34
Quick Ratio
9.40
2.44
Cash flow (trailing twelve months)
Measure
Virax Biolabs
Industry median
Operating Cash Flow
-$4.62M
-$12.35M
Capital Expenditures
-$255.83K
-$1.08M
Free Cash Flow
-$4.88M
-$20.22M
FCF Per Share
-$8.42
-$0.42
Efficiency
Measure
Virax Biolabs
Industry median
Asset Turnover
0.00
0.39
Inventory Turnover
0.10
2.70
Dividends and yields
Measure
Virax Biolabs
Industry median
Earnings Yield
-619.5%
-23.3%
FCF Yield
-601.5%
-8.72%
Buyback Yield
-343.2%
-0.59%
Shareholder Yield
-343.2%
0.00%
Shares
Measure
Virax Biolabs
Industry median
Shares Outstanding
579,218
58,127,000
Shares Change (YoY)
166.5%
10.9%
Float
210,648
49,136,700
Shares Held by Insiders
63.6%
11.6%
Taxes
Measure
Virax Biolabs
Industry median
Income Tax
-$900.24K
$79.87K
Scores
Measure
Virax Biolabs
Industry median
Altman Z-Score
-6.14
-0.22
Piotroski F-Score
6
4
Calculated by StockData from Virax Biolabs's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.